Korro to Cut 34% of Its Workforce; Shares Drop Sharply
Korro Bio's Financial Results: Korro Bio, Inc. reported a net loss of $18.1 million for Q3 2025, with a significant drop in stock price by over 77% due to mixed clinical data and a strategic restructuring, including a 34% workforce reduction.
KRRO-110 Development Update: The lead candidate KRRO-110, targeting Alpha-1 Antitrypsin Deficiency, showed initial success in producing functional protein but fell short of the protective threshold, prompting a shift to a GalNAc-conjugated version expected in 2026.
KRRO-121 Pipeline Expansion: Korro has nominated KRRO-121 for development, aimed at treating hyperammonaemia and urea cycle disorders, with plans for regulatory filing for first-in-human trials in late 2026.
Strategic Restructuring and Future Plans: The company is focusing on advancing its GalNAc-conjugated pipeline for liver-based indications while extending its cash runway into 2027, ending Q3 2025 with $102.5 million in cash and equivalents.
Trade with 70% Backtested Accuracy
Analyst Views on KRRO
About KRRO
About the author
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades
- Analyst Upgrades: H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, asserting that KRRO-121 serves as an independently risk-mitigated asset, thereby enhancing market confidence in the stock.
- Stock Price Surge: Shares of Korro Bio jumped 13% on Thursday following optimistic upgrades from multiple analysts, indicating strong market confidence in the new drug development candidate KRRO-121, which is likely to attract more investor interest.
- Clinical Trial Plans: Korro intends to file for clinical trials of KRRO-121 in the second half of 2026, targeting hyperammonemia treatment, which could present new growth opportunities for the company in addressing this critical metabolic condition.
- Market Sentiment Shift: Retail sentiment on Stocktwits for KRRO stock shifted from ‘bearish’ to ‘extremely bullish’ in the past 24 hours, with message volume increasing from ‘high’ to ‘extremely high’, reflecting strong optimism among investors regarding the company’s prospects.
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, providing investors with a comprehensive view of market analysis to better seize investment opportunities.
- Investor Attention: The changes in analyst ratings may draw investor interest towards FTNT stock, particularly in the current market environment where investors need to closely monitor these shifts for informed decision-making.
- Market Impact Assessment: Analyst rating adjustments not only affect the performance of individual stocks but can also influence overall market sentiment, prompting investors to consider these factors to optimize their investment portfolios.
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
Dow's Significant Decline Following Record High is Uncommon: Concerns Over December Rate Cut Impacting Wall Street.
Market Performance: Major U.S. equity indexes experienced significant declines, marking their worst percentage-point drops since October 10.
Affected Indexes: The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all reported substantial losses on the same day.
William Blair Lowers Korro Bio Rating to Market Perform
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Korro Bio's Initial Trial Results Disappoint; Shares Reach Record Low
Stock Performance: Korro Bio, Inc. (NASDAQ: KRRO) experienced a significant decline in stock price, dropping 80% to $6.27, with a trading volume of 6.68 million shares compared to the average of 1.42 million.
Clinical Trial Update: The company reported that its KRRO-110 treatment for alpha-1 antitrypsin deficiency (AATD) produced functional M-AAT protein in patients, but did not meet the expected protein levels based on preclinical data.
Strategic Restructuring: Korro is implementing a workforce reduction of approximately 34% to focus on advancing its GalNAc-conjugated programs and extending its cash runway into the second half of 2027.
Analyst Downgrade: William Blair downgraded Korro's stock from Outperform to Market Perform, citing concerns over the competitiveness of KRRO-110 and the pause in collaboration with Novo Nordisk.
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades
- Analyst Upgrades: H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, asserting that KRRO-121 serves as an independently risk-mitigated asset, thereby enhancing market confidence in the stock.
- Stock Price Surge: Shares of Korro Bio jumped 13% on Thursday following optimistic upgrades from multiple analysts, indicating strong market confidence in the new drug development candidate KRRO-121, which is likely to attract more investor interest.
- Clinical Trial Plans: Korro intends to file for clinical trials of KRRO-121 in the second half of 2026, targeting hyperammonemia treatment, which could present new growth opportunities for the company in addressing this critical metabolic condition.
- Market Sentiment Shift: Retail sentiment on Stocktwits for KRRO stock shifted from ‘bearish’ to ‘extremely bullish’ in the past 24 hours, with message volume increasing from ‘high’ to ‘extremely high’, reflecting strong optimism among investors regarding the company’s prospects.
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, providing investors with a comprehensive view of market analysis to better seize investment opportunities.
- Investor Attention: The changes in analyst ratings may draw investor interest towards FTNT stock, particularly in the current market environment where investors need to closely monitor these shifts for informed decision-making.
- Market Impact Assessment: Analyst rating adjustments not only affect the performance of individual stocks but can also influence overall market sentiment, prompting investors to consider these factors to optimize their investment portfolios.
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
Dow's Significant Decline Following Record High is Uncommon: Concerns Over December Rate Cut Impacting Wall Street.
Market Performance: Major U.S. equity indexes experienced significant declines, marking their worst percentage-point drops since October 10.
Affected Indexes: The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all reported substantial losses on the same day.
William Blair Lowers Korro Bio Rating to Market Perform
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Korro Bio's Initial Trial Results Disappoint; Shares Reach Record Low
Stock Performance: Korro Bio, Inc. (NASDAQ: KRRO) experienced a significant decline in stock price, dropping 80% to $6.27, with a trading volume of 6.68 million shares compared to the average of 1.42 million.
Clinical Trial Update: The company reported that its KRRO-110 treatment for alpha-1 antitrypsin deficiency (AATD) produced functional M-AAT protein in patients, but did not meet the expected protein levels based on preclinical data.
Strategic Restructuring: Korro is implementing a workforce reduction of approximately 34% to focus on advancing its GalNAc-conjugated programs and extending its cash runway into the second half of 2027.
Analyst Downgrade: William Blair downgraded Korro's stock from Outperform to Market Perform, citing concerns over the competitiveness of KRRO-110 and the pause in collaboration with Novo Nordisk.
